Aclaris Therapeutics(ACRS) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti- TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI- 052 - Pipeline: Oral Inhibitors: ITK Franchise ● Announced Anticipated Phase 2 Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3, in an Additional Indication: Aclaris expects to fur ...